Entering text into the input field will update the search result below

Heron stock falls 21% as Q4 sales remain largely flat Y/Y

Mar. 01, 2022 10:38 AM ETHeron Therapeutics, Inc. (HRTX)By: Ravikash, SA News Editor2 Comments

Stock Market Data

blackred/E+ via Getty Images

Heron Therapeutics (HRTX -21.3%) stock fell following its Q4 results.

Q4 net product sales rose +0.24% Y/Y to $20.66M, which failed to beat analysts' estimates.

Net product sales for ZYNRELEF were $0.8M in Q4. The pain drug became

Recommended For You

Comments (2)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

ZYNRELEF was/is a promising product. What a shame that it’s in the hands of an incompetent management.
@avainan agreed. They’ve been pretty unlucky with covid etc and elective surgeries being delayed for years. Let’s hope it’s a slow burner and will start catching up to its potential this year. I’d say there’s a good chance it will.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.